Nexstim Balans Gezondheid

Financiële gezondheid criteriumcontroles 4/6

Nexstim heeft een totaal eigen vermogen van €1.9M en een totale schuld van €6.3M, wat de schuld-eigenvermogensverhouding op 337.9% brengt. De totale activa en totale passiva bedragen respectievelijk €11.2M en €9.3M.

Belangrijke informatie

337.9%

Verhouding schuld/eigen vermogen

€6.31m

Schuld

Rente dekkingsratio	n/a
Contant	€3.03m
Aandelen	€1.87m
Totaal verplichtingen	€9.32m
Totaal activa	€11.19m

Recente financiële gezondheidsupdates

Recent updates

Analyse van de financiële positie

Kortlopende schulden: De korte termijn activa ( €6.7M ) 5NX } overtreffen de korte termijn passiva ( €4.5M ).

Langlopende schulden: De kortetermijnactiva 5NX ( €6.7M ) overtreffen de langetermijnschulden ( €4.9M ).

Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: De netto schuld/eigen vermogen ratio ( 175.6% ) 5NX wordt als hoog beschouwd.

Schuld verminderen: 5NX had 5 jaar geleden een negatief eigen vermogen, maar is nu positief en is dus verbeterd.

Balans

Analyse van de cashflow

Voor bedrijven die in het verleden gemiddeld verliesgevend zijn geweest, beoordelen we of ze ten minste 1 jaar kasstroom hebben.

Stabiele cash runway: 5NX heeft op basis van de huidige vrije kasstroom voldoende kasstroom voor meer dan een jaar.

Voorspelling contante baan: Er zijn onvoldoende gegevens om te bepalen of 5NX voldoende cash runway heeft als de vrije kasstroom blijft groeien of krimpen op basis van historische percentages.

Nexstim Balans Gezondheid

Financiële gezondheid criteriumcontroles 4/6

Belangrijke informatie

Recente financiële gezondheidsupdates

Nexstim Applies for Delisting Regarding the Secondary Listing of its Shares from Nasdaq First North Growth Market Sweden

Recent updates

Nexstim Plc to Report Fiscal Year 2024 Results on Feb 27, 2025

Nexstim plc Receives Approval from Health Canada for the Marketing and Commercial Distribution of Its NBS 6 System for the Treatment of Major Depressive Disorder

Nexstim Plc Updates Earnings Guidance for the Year 2023

Nexstim Plc, Annual General Meeting, Mar 28, 2024

Nexstim Plc to Report Fiscal Year 2023 Final Results on Mar 06, 2024

Nexstim Plc Releases New System Functionalities for Research Use in Europe

Nexstim Plc to Report Q3, 2023 Results on Oct 27, 2023

Nexstim plc Announces Board Appointments

Nexstim Plc to Report Fiscal Year 2023 Results on Feb 27, 2024

Nexstim plc Provides Overview of Pilot Study Results in Treatment of Severe Depression with Nexstim Nbt®? System At Kuopio University Hospital

Nexstim Applies for Delisting Regarding the Secondary Listing of its Shares from Nasdaq First North Growth Market Sweden

Nexstim Plc, Annual General Meeting, Mar 31, 2023

Nexstim Reports Excellent Treatment Outcomes of over 400 MDD Patients in Patient Registry

Nexstim plc Appoints Tero Weckroth as A New Member of the Nomination Committee

First half 2022 earnings released

Nexstim Plc Provides Earnings Guidance for the Year 2022

High number of new and inexperienced directors

High number of new and inexperienced directors

Forecast to breakeven in 2022

Full year 2021 earnings: Revenues exceed analyst expectations

Nexstim Reaches Over 300 Completed Treatment Sessions – Continues to Report a Remission Rate Greater than 50% of MDD Patients in the Patient Registry

Nexstim Plc Announces Results of the Pilot Study in Chronic Pain Treatment At Helsinki University Hospital

Nexstim Plc Receives System Orders from Existing Hospital Customers in Finland

Nexstim Announces Continuation of Pilot Study in Treatment of Severe Depression at Kuopio University Hospital

First half 2021 earnings released: €0.17 loss per share (vs €1.25 loss in 1H 2020)

Nexstim Plc Provides Update on Pilot Study in Chronic Pain Treatment at Helsinki University Hospital

Nexstim Plc Continues to Report Very Promising MDD Treatment Outcomes with Remission Rate Greater Than 50%

Nexstim Plc Granted Authorization for Commercial Distribution of NBS System in Australia

Nexstim Gives an Update on its Promising Treatment Results of Major Depressive Disorder

Nexstim plc Receives Two NBS System Orders from Hospitals in Norway and the Us

Nexstim plc Provides Encouraging Results of the Initial Pilot Study in Severe Depression At Kuopio University Hospital

Full year 2020 earnings released

Revenue beats expectations

German University Hospital Orders Nexstim NBS System with NexSpeech

Rohan Hoare and Tomas Holmberg No Longer Be Available to Nexstim Plc's Board of Directors for the Period 2021-2022

Nexstim plc Receives Three New NBS System Orders

Nexstim Plc Receives Two New NBT® System Purchase Orders in the United States

Nexstim plc Provides an Update on the Pilot Study in Severe Depression At Kuopio University Hospital

Nexstim Plc Receives an Order and Signs Purchase Agreement to Develop Two Prototype Systems Enabling Introduction of Novel Research Tool for Probing and Diagnosing the Brain

Nexstim plc Continues to Report Promising Results in Quickly Growing Number of Patients Completing SmartFocus rTMS Treatment of Major Depressive Disorder

Pilot Study for New Depression Treatment Protocol with Nexstim NBT® System Starts in Kuopio University Hospital

Nexstim plc Receives Two Nbs System Upgrade Orders in the United States

Earnings released

Analyse van de financiële positie

Schuld/ eigen vermogen geschiedenis en analyse

Balans

Analyse van de cashflow

Ontdek gezonde bedrijven